title: [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
abstract: In haematological malignancies, molecular markers like fusion DNA from balanced translocations, point mutations, or over-expressed genes can now be used not only for diagnosis, but also for determination of the minimal residual disease (MRD) after cytoreduction with a sensitivity by far exceeding that of previous methodologies. The sensitivity of quantitative polymerase chain reaction typically reaches a validated identification of 1 malignant cell in 100,000.
authors.affiliation: Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C. phokland@ki.au.dk
authors.forename: Peter
authors.initials: P
authors.lastname: Hokland
authors.forename: Charlotte Guldborg
authors.initials: CG
authors.lastname: Nyvold
authors.forename: Jesper
authors.initials: J
authors.lastname: Stentoft
authors.forename: Hans Beier
authors.initials: HB
authors.lastname: Ommen
authors.forename: Lene Hyldahl
authors.initials: LH
authors.lastname: Ebbesen
authors.forename: Karin
authors.initials: K
authors.lastname: Braendstrup
authors.forename: Bodil Lind
authors.initials: BL
authors.lastname: Andersen
authors.forename: Lone Siig
authors.initials: LS
authors.lastname: Mikkelsen
authors.forename: Mette
authors.initials: M
authors.lastname: Ostergaard
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D006801:Humans; D007938:Leukemia / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics; D016133:Polymerase Chain Reaction / Q000379:methods*; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor